Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus - Wikidata - wikimedia - TriplyDB

Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus

Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus

http://www.wikidata.org/entity/Q28379074

about

Sub-inhibitory concentrations of vancomycin prevent quinolone-resistance in a penicillin-resistant isolate of Streptococcus pneumoniae Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.Penicillin-binding protein gene alterations in Streptococcus uberis isolates presenting decreased susceptibility to penicillin Natural variability of in vitro adherence to fibrinogen and fibronectin does not correlate with in vivo infectivity of Staphylococcus aureus.Haemin represses the haemolytic activity of Staphylococcus aureus in an Sae-dependent manner.Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus Teicoplanin stress-selected mutations increasing sigma(B) activity in Staphylococcus aureus.Influence of a functional sigB operon on the global regulators sar and agr in Staphylococcus aureus Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review MsrR, a putative cell envelope-associated element involved in Staphylococcus aureus sarA attenuation.In vivo effect of flucloxacillin in experimental endocarditis caused by mecC-positive staphylococcus aureus showing temperature-dependent susceptibility in vitro Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis.De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers.Staphylococcus aureus mutants lacking the LytR-CpsA-Psr family of enzymes release cell wall teichoic acids into the extracellular medium De novo designed synthetic mimics of antimicrobial peptides.LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus.Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro.Mutations in penicillin-binding protein (PBP) genes and in non-PBP genes during selection of penicillin-resistant Streptococcus gordonii.Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters.Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.Painful nodule with induration and spreading erythema.Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

P2860

Q24801022-D2AA7198-16C7-4EC8-A4E3-96114353B18D Q28361569-DC444581-8F00-4709-883C-B77D4A7F0AA4 Q33553795-A94EE7B6-05A2-410D-9693-E34F9C38F4FA Q33676380-0ADA6E0D-E6D5-4630-AAEC-25DE9DFA51DB Q33768982-81EBD11F-EB52-4C07-9FE1-058635073C8B Q33852326-505159B2-701B-43E6-ADFD-17CE137702C7 Q33978084-3E15440C-9297-4CA2-AB03-5FB1A9A7006F Q33982248-28ED7751-A731-445A-AE9A-E48094DD0390 Q33996758-8577861B-8E40-4581-AAD1-57EA2FD37BA6 Q34107094-BB5E000B-206A-4077-88A6-0D54FBCC1953 Q35005511-255BAB5F-AB05-4BE7-89A4-60DE3F4F4FBF Q35119494-162A3D31-D95A-4A9D-94BC-A71AB1EBBD6C Q35165812-6A0DF190-BECB-4CA2-B1D6-225CD5E43745 Q35168910-A177125C-EA75-459A-9926-A85E04B279BB Q35759063-0FC3A447-1971-48CA-A145-F259E754F3FD Q37154488-74DC9B03-55B7-4F40-81A3-E0FC9924E675 Q37253009-0BD5C663-C481-470E-ABED-6BCF8F3CD59A Q37321460-CC04D41E-C9A0-4541-81DB-494E3629A8DF Q37598693-F385A64D-4502-401F-B35A-1A38DF53B212 Q39469535-C1A36701-9ED9-4EF1-8048-62CB5D015B68 Q39558184-65D21AC7-2104-4091-9495-B0E85F4853B0 Q39559768-C1BA3763-D39A-463C-B8A7-F4DDC0A553D3 Q39792641-A685CE8B-68FD-4FEC-A18A-82AFFAC7AD8D Q40902267-0B599DD4-D984-4182-BD01-A5223DA5BD2C Q41831644-E63F101B-8414-49AC-ABA9-62D3187C63A5 Q41992616-B96D6838-0634-4A79-83D6-AD12DE78CB11 Q42575024-8FAD5267-57EA-4104-9809-631E2CC43549 Q42719368-80DE906E-D87F-4115-B3CE-B78B45627241

P2860

Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus

http://www.wikidata.org/entity/Q28379074

description

1997 nî lūn-bûn

@nan

1997 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Levofloxacin versus ciprofloxa ...... esistant Staphylococcus aureus

@ast

Levofloxacin versus ciprofloxa ...... esistant Staphylococcus aureus

@en

Levofloxacin versus ciprofloxa ...... esistant Staphylococcus aureus

@nl

type

label

Levofloxacin versus ciprofloxa ...... esistant Staphylococcus aureus

@ast

Levofloxacin versus ciprofloxa ...... esistant Staphylococcus aureus

@en

Levofloxacin versus ciprofloxa ...... esistant Staphylococcus aureus

@nl

prefLabel

Levofloxacin versus ciprofloxa ...... esistant Staphylococcus aureus

@ast

Levofloxacin versus ciprofloxa ...... esistant Staphylococcus aureus

@en

Levofloxacin versus ciprofloxa ...... esistant Staphylococcus aureus

@nl

P1433

Q28379074-2A8BC10D-2086-4AA4-8D0F-35AD4DC7513E

P1476

Q28379074-2A8ABE4F-9A26-4E26-888E-53A9B812C516

P2093

Q28379074-0FAF4DC7-9A8D-4008-BDFB-88F306DBC7D2

Q28379074-16E52948-7F97-418A-80CB-1504549C2199

Q28379074-4B92147A-1490-4D68-8643-9AB84D7DD0BA

Q28379074-8584D151-94E6-4F54-B646-B7AC8131AF5D

P2860

Q28379074-0F8F8A78-2A07-4929-B967-B0C0B373D44A

Q28379074-3AB8644A-CA61-4F37-90AC-A3FF86F154A4

Q28379074-416B1AA2-6283-4752-BAA7-CE9467449588

Q28379074-474FFA4C-0646-4000-BB7C-1EE6A9A73C3A

Q28379074-52B33C88-2D8C-4C3C-9BB0-4F12F4C2F65E

Q28379074-66C8A7B1-FFFA-422F-A5EC-0D9F094EA3B0

Q28379074-684FBB8C-5952-4BE8-90E7-7D0849A9DB47

Q28379074-71779A15-96D7-42EC-8B2C-D14FDE40807E

Q28379074-7A79F4F9-DC60-41AC-8C4B-CE4EC56EC191

Q28379074-84FCA1AE-F2FB-43AA-B646-A4AEE40E7740

P304

Q28379074-9EF4FE69-5B77-44E5-9A74-8DCCD4651262

P31

Q28379074-C65C387F-DBCE-42BE-AAEE-389C9C2F4F93

P356

Q28379074-61DBA92B-0888-4EAB-89D5-9547C73BE43D

P407

Q28379074-46C74305-92E5-498D-8A03-B0757AF0E5EE

P433

Q28379074-5CA1A213-0556-4058-A77D-CB7390750807

P478

Q28379074-E12B90FF-81CC-4B28-88E5-2DDE5CB0B6B9

P577

Q28379074-03B5F005-AA8E-47CE-9D8B-9533A7B0B5F7

P698

Q28379074-ED439DD2-8701-4E4A-8AA2-625376E01CCC

P921

Q28379074-00382148-4F67-409E-9F93-B3AC70F4894E

P932

Q28379074-9C6D3586-B0D4-4D6F-92AD-6EBA44921D17

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Levofloxacin versus ciprofloxa ...... esistant Staphylococcus aureus

@en

P2093

Entenza JM

http://www.w3.org/2001/XMLSchema#string

Glauser MP

http://www.w3.org/2001/XMLSchema#string

Moreillon P

http://www.w3.org/2001/XMLSchema#string

Vouillamoz J

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.

Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.

Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association.

Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones

Concentrations of flucloxacillin in heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery

In vitro activity of DR-3355, an optically active ofloxacin

Vancomycin pharmacokinetics in normal and morbidly obese subjects

Natural history of aortic valve endocarditis in rats

Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections.

P304

1662-1667

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.41.8.1662

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

1997-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9257737

http://www.w3.org/2001/XMLSchema#string

P921

methicillin-resistant Staphylococcus aureus

P932

163981

http://www.w3.org/2001/XMLSchema#string